Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Specific Immunotherapy in Hepatocellular Cancer: A Systematic Review Publisher Pubmed



Baradaran Noveiry B1 ; Hirbodmobarakeh A1, 2, 3 ; Khalili N1 ; Hourshad N1 ; Greten TF4 ; Aboualfa GK5, 6 ; Rezaei N1, 2, 3, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Border of Immune Tolerance Education and Research Network (BITERN), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  2. 2. Molecular Immunology Research Center, Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States
  5. 5. Memorial Sloan Kettering Cancer Center, New York, United States
  6. 6. Weill Cornell Medical College, New York, United States
  7. 7. Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Sheffield, United Kingdom

Source: Journal of Gastroenterology and Hepatology (Australia) Published:2017


Abstract

Background and Aim: In recent years, several novel immunotherapeutic approaches were developed and investigated in patients with hepatocellular carcinoma (HCC). We designed this systematic review, to evaluate clinical efficacy of specific immunotherapy in patients with HCC, according to the guidelines of Border of Immune Tolerance Education and Research Network (BITERN) and Cochrane collaboration. Methods: We searched Medline, Scopus, CENTRAL, TRIP, DART, OpenGrey, and ProQuest through the 9th of December 2015. One author reviewed and retrieved citations from these seven databases for irrelevant and duplicate studies, and two other authors independently extracted data from the studies and rated their quality. We collated study findings and calculated a weighted treatment effect across studies using Review Manager. Results: We found 12144 references in seven databases of which 21 controlled studies with 1885 HCC patients in different stages were included in this systematic review after the primary and secondary screenings. Overall, patients undergoing specific immunotherapy had significantly higher overall survival than those in control group (HR = 0.59; 95% CI = 0.47–0.76, P < 0.0001). There was a significant difference in recurrence-free survival between patients undergoing specific immunotherapy and patients in control groups and patients in immunotherapy groups overall had less recurrence than control group (HR = 0.54; 95% CI = 0.46–0.63, P < 0.00001). Conclusions: Results of this systematic review based on the available literature suggest that overall specific immunotherapeutic approaches could be beneficiary for the treatment of patients with HCC. This further supports the current and ongoing evaluations of specific immunotherapies in the field. © 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
Related Docs
1. Combinational Immune? Cell Therapy of Natural Killer Cells and Sorafenib for Advanced Hepatocellular Carcinoma: A Review, Cancer Cell International (2018)
2. Antigen-Independent Killer Cells Prepared for Adoptive Immunotherapy: One Source, Divergent Protocols, Diverse Nomenclature, Journal of Immunological Methods (2020)
3. Immune Landscape of Hepatocellular Carcinoma: From Dysregulation of the Immune Responses to the Potential Immunotherapies, Cell Biochemistry and Function (2024)
4. Tumor Immunology, Clinical Immunology (2022)
5. Specific Immunotherapy in Renal Cancer: A Systematic Review, Therapeutic Advances in Urology (2017)
6. Advanced Therapeutic Modalities in Hepatocellular Carcinoma: Novel Insights, Journal of Cellular and Molecular Medicine (2021)
7. The Effects of Sorafenib and Natural Killer Cell Co-Injection in Combinational Treatment of Hepatocellular Carcinoma; an in Vivo Approach, Pharmacological Reports (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (3)
Iman Seyhoun (2)